2015 Emerging Science Program Schedule Following is the schedule of Emerging Science abstracts to be presented at the 2015 AAN Annual Meeting. Abstracts qualify for Emerging Science presentations by having key aspects of research conducted after the October 27th abstract submission deadline and must be new and of sufficient scientific importance to warrant expedited presentation and publication. The Science Committee is committed to presenting the best neuroscientific research at the Annual Meeting so we are excited to announce that we are accepting 14 abstracts for dual presentation this year and 7 abstracts as poster presentations. The 14 dual presentation abstracts will be featured in data blitz format during the first 45 minutes of the Emerging Science Platform session from 6:15 p.m. to 7:00 p.m., followed by poster presentations in the same room from 7:00 p.m. to 7:45 p.m. A total of 7 poster presentation abstracts will be included in Poster Session 4 on Wednesday, April 22 from 7:30 a.m. to 12:00 p.m. Emerging Science Platform Session – 6:15 p.m. – 7:45 p.m., Wednesday, April 22, 2015 001- “RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE IB STUDY OF ADUCANUMAB (BIIB037), AN ANTI-AB MONOCLONAL ANTIBODY, IN PATIENTS WITH PRODROMAL OR MILD ALZHEIMER’S DISEASE: INTERIM RESULTS BY DISEASE STAGE AND APOE4 STATUS” Jeffrey J. Sevigny, MD, Cambridge, MA 002- “Imaging microglial/macrophage activation in the early stage of Alzheimer's disease: a PET study using [18F]DPA-714 coupled with PiB” Lorraine Hamelin, Paris, France 003- “The burden of neurological disorders (1990-2013); preliminary findings of the Global Burden of Disease 2013 study” Maziar Moradi-Lakeh, MD, MPH, Seattle, WA 004- “Phase I/II Trial of SAGE-547 in Super-Refractory Status Epilepticus” Stephen Kanes, MD, PhD, Cambridge, MA 005- “Epidiolex (Cannabidiol) in Treatment Resistant Epilepsy” Orrin Devinsky, MD, FAAN, New York, NY 006- “Oral fingolimod versus placebo in patients with primary progressive multiple sclerosis (PPMS): results of the INFORMS phase III trial” Fred D. Lublin, MD, FAAN, New York, NY 007- “PML risk stratification using anti-JCV antibody index and L-selectin (CD62L)” Nicholas Schwab, PhD, Münster, Germany 008- “Evidence of Remyelination with the Anti-LINGO-1 Monoclonal Antibody BIIB033 After Acute Optic Neuritis” Diego Cadavid, MD, FAAN, Concord, MA 009- “Subcutaneous natalizumab 300mg every 4 weeks is comparable to standard intravenous dosing in REFINE: a study exploring the safety, tolerability, and efficacy of multiple natalizumab treatment regimens in patients with relapsing multiple sclerosis” Maria Trojano, Bari, Italy 010- “NNZ-2566: A Novel, Experimental Treatment for Adolescent and Adult Females with Rett Syndrome” Daniel G. Glaze, MD, Houston, TX 011- “SMN2 splicing modifier RG7800 shows dose-dependent increase of full length SMN2 mRNA in first-in-human study” Heidemarie Kletzl, PharmD, PhD, Basel, Switzerland 012- “First Time Use of SD-809 in Huntington Disease (First-HD)” Samuel A. Frank, MD, Boston, MA 013- “TOPICALLY APPLIED KETOPROFEN GEL (ELS-M11) IN THE TREATMENT OF SEVERE MIGRAINE PAIN” Wolfgang Liedtke, MD, PhD, Durham, NC 014- “OnabotulinumtoxinA treatment in adult patients with post-stroke lower limb spasticity: Results from a double-blind, placebo-controlled, phase 3 clinical trial” Theodore Wein, MD, Montreal, Quebec Emerging Science Poster Presentations- Poster Session 4 – 7:30 a.m. – 12:00 p.m., Wednesday, April 22, 2015 P4.336- “Triheptanoin dramatically reduces the frequency of paroxysmal movement disorders in GLUT1 deficiency” Fanny Mochel, MD, Bethesda, MD P4.337- “Pharmacokinetic-Pharmacodynamic effects of sublingual apomorphine (APL-130277) for acute rescue of OFF episodes in Parkinson's disease patients” Jordan Dubow, Northbrook, IL P4.338- “Characterization of absolute lymphocyte count profiles in MS patients treated with delayedrelease dimethyl fumarate: considerations for patient management” Robert J. Fox, MD, FAAN, Cleveland, OH P4.339- “Safety and Tolerability of the Remyelinating Therapeutic Antibody rHIgM22 in Patients with Stable Multiple Sclerosis” Benjamin M. Greenberg, MD, Dallas, TX P4.340- “Progressive Multifocal Leukoencephalopathy Not Observed Later Than Six Months After Natalizumab Discontinuation” Sarah Gheuens, Cambridge, MA P4.341- “Chronic Treatment with PB1046, a stable and long-acting vasoactive intestinal peptide receptor agonist, improves cardiac and skeletal muscle function in mouse models of Duchenne Muscular Dystrophy” Steve Roof, Columbus, OH P4.342- “Direct cis-differentiation of Accessible Neuronal Precursors to Model Neurologic Disease in Mice and Humans” Andrew Liu, MD, New Haven, CT